Pharmaceutical company Allergan (Dublin) spotted an opportunity to add an implantable shunt technology to its eye care offering through a $300 million cash acquisition of privately held Aquesys (Aliso Viejo, Calif.). The deal also includes regulatory and commercialization payments for an undisclosed amount. Aquesys' lead product is XEN45, a soft shunt that is implanted in the subconjunctival space in the eye through a minimally invasive procedure with a single use, pre-loaded injector. The deal is expected to close in 4Q15. Read More
